Volume 21: Issue 3 (Aug 2022): Transplantation

Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al.: The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 20: 2318–2331, 2020 PubMed

Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, : The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 20: 2318–2331, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Nankivell BJ, Shingde M, Keung KL, Fung CL, Borrows RJ, O’Connell PJ, et al.: The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion. Am J Transplant 18: 364–376, 2018 PubMed

Nankivell BJ, Shingde M, Keung KL, Fung CL, Borrows RJ, O’Connell PJ, : The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion. Am J Transplant 18: 364–376, 2018PubMed)| false
• Search Google Scholar
• Export Citation

Mannon RB, Matas AJ, Grande J, Leduc R, Connett J, Kasiske B, et al.; DeKAF Investigators: Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant 10: 2066–2073, 2010 PubMed

Mannon RB, Matas AJ, Grande J, Leduc R, Connett J, Kasiske B, ; DeKAF Investigators: Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant 10: 2066–2073, 2010PubMed)| false
• Search Google Scholar
• Export Citation

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al.: The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 18: 293–307, 2018 PubMed

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, : The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 18: 293–307, 2018PubMed)| false
• Search Google Scholar
• Export Citation

Nakagawa K, Tsuchimoto A, Ueki K, Matsukuma Y, Okabe Y, Masutani K, et al.; Japan Academic Consortium of Kidney Transplantation Investigators: Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification: Surveillance by 1-year protocol biopsies for kidney transplantation. Am J Transplant 21: 174–185, 2021 PubMed

Nakagawa K, Tsuchimoto A, Ueki K, Matsukuma Y, Okabe Y, Masutani K, ; Japan Academic Consortium of Kidney Transplantation Investigators: Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification: Surveillance by 1-year protocol biopsies for kidney transplantation. Am J Transplant 21: 174–185, 2021PubMed)| false
• Search Google Scholar
• Export Citation

Matas AJ, Helgeson ES, Gaston R, Cosio F, Mannon R, Kasiske BL, et al.: Inflammation in areas of fibrosis: The DeKAF prospective cohort. Am J Transplant 20: 2509–2521, 2020 PubMed

Matas AJ, Helgeson ES, Gaston R, Cosio F, Mannon R, Kasiske BL, : Inflammation in areas of fibrosis: The DeKAF prospective cohort. Am J Transplant 20: 2509–2521, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Schinstock CA, Sapir-Pichhadze R, Naesens M, Batal I, Bagnasco S, Bow L, et al.: Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications. Am J Transplant 19: 123–131, 2019 PubMed

Schinstock CA, Sapir-Pichhadze R, Naesens M, Batal I, Bagnasco S, Bow L, : Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications. Am J Transplant 19: 123–131, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Callemeyn J, Ameye H, Lerut E, Senev A, Coemans M, Van Loon E, et al.: Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. Am J Transplant 21: 2413–2423, 2021 PubMed

Callemeyn J, Ameye H, Lerut E, Senev A, Coemans M, Van Loon E, : Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. Am J Transplant 21: 2413–2423, 2021PubMed)| false
• Search Google Scholar
• Export Citation

Mengel M, Loupy A, Haas M, Roufosse C, Naesens M, Akalin E, et al.: Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transplant 20: 2305–2317, 2020 PubMed

Mengel M, Loupy A, Haas M, Roufosse C, Naesens M, Akalin E, : Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transplant 20: 2305–2317, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Clayton PA, McDonald SP, Russ GR, Chadban SJ: Long-term outcomes after acute rejection in kidney transplant recipients: An ANZDATA analysis. J Am Soc Nephrol 30: 1697–1707, 2019 PubMed

Clayton PA, McDonald SP, Russ GR, Chadban SJ: Long-term outcomes after acute rejection in kidney transplant recipients: An ANZDATA analysis. J Am Soc Nephrol 30: 1697–1707, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Van Loon E, Senev A, Lerut E, Coemans M, Callemeyn J, Van Keer JM, et al.: Assessing the complex causes of kidney allograft loss. Transplantation 104: 2557–2566, 2020 PubMed

Van Loon E, Senev A, Lerut E, Coemans M, Callemeyn J, Van Keer JM, : Assessing the complex causes of kidney allograft loss. Transplantation 104: 2557–2566, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Hoffman W, Mehta R, Jorgensen DR, Sood P, Randhawa P, Wu CM, et al.: The impact of early clinical and subclinical T cell-mediated rejection after kidney transplantation. Transplantation 103: 1457–1467, 2019 PubMed

Hoffman W, Mehta R, Jorgensen DR, Sood P, Randhawa P, Wu CM, : The impact of early clinical and subclinical T cell-mediated rejection after kidney transplantation. Transplantation 103: 1457–1467, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Gupta A, Broin PO, Bao Y, Pullman J, Kamal L, Ajaimy M, et al.: Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. Kidney Int 89: 217–225, 2016 PubMed

Gupta A, Broin PO, Bao Y, Pullman J, Kamal L, Ajaimy M, : Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. Kidney Int 89: 217–225, 2016PubMed)| false
• Search Google Scholar
• Export Citation

Grafft CA, Cornell LD, Gloor JM, Cosio FG, Gandhi MJ, Dean PG, et al.: Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol Dial Transplant 25: 307–310, 2010 PubMed

Grafft CA, Cornell LD, Gloor JM, Cosio FG, Gandhi MJ, Dean PG, : Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol Dial Transplant 25: 307–310, 2010PubMed)| false
• Search Google Scholar
• Export Citation

Parajuli S, Redfield RR, Garg N, Aziz F, Mohamed M, Astor BC, et al.: Clinical significance of microvascular inflammation in the absence of anti-HLA DSA in kidney transplantation. Transplantation 103: 1468–1476, 2019 PubMed

Parajuli S, Redfield RR, Garg N, Aziz F, Mohamed M, Astor BC, : Clinical significance of microvascular inflammation in the absence of anti-HLA DSA in kidney transplantation. Transplantation 103: 1468–1476, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Sis B, Jhangri GS, Riopel J, Chang J, de Freitas DG, Hidalgo L, et al.: A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 12: 1168–1179, 2012 PubMed

Sis B, Jhangri GS, Riopel J, Chang J, de Freitas DG, Hidalgo L, : A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 12: 1168–1179, 2012PubMed)| false
• Search Google Scholar
• Export Citation

Senev A, Coemans M, Lerut E, Van Sandt V, Daniëls L, Kuypers D, et al.: Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome. Am J Transplant 19: 763–780, 2019 PubMed

Senev A, Coemans M, Lerut E, Van Sandt V, Daniëls L, Kuypers D, : Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome. Am J Transplant 19: 763–780, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Senev A, Lerut E, Van Sandt V, Coemans M, Callemeyn J, Sprangers B, et al.: Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation. Am J Transplant 19: 3100–3113, 2019 PubMed

Senev A, Lerut E, Van Sandt V, Coemans M, Callemeyn J, Sprangers B, : Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation. Am J Transplant 19: 3100–3113, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Lefaucheur C, Louis K, Philippe A, Loupy A, Coates PT: The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond. Kidney Int 100: 787–798, 2021 PubMed

Lefaucheur C, Louis K, Philippe A, Loupy A, Coates PT: The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond. Kidney Int 100: 787–798, 2021PubMed)| false
• Search Google Scholar
• Export Citation

Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, et al.: Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int 96: 189–201, 2019 PubMed

Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, : Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int 96: 189–201, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Davis S, Gralla J, Klem P, Stites E, Wiseman A, Cooper JE: Tacrolimus intrapatient variability, time in therapeutic range, and risk of de novo donor-specific antibodies. Transplantation 104: 881–887, 2020 PubMed

Davis S, Gralla J, Klem P, Stites E, Wiseman A, Cooper JE: Tacrolimus intrapatient variability, time in therapeutic range, and risk of de novo donor-specific antibodies. Transplantation 104: 881–887, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Gonzales HM, McGillicuddy JW, Rohan V, Chandler JL, Nadig SN, Dubay DA, et al.: A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant 20: 1969–1983, 2020 PubMed

Gonzales HM, McGillicuddy JW, Rohan V, Chandler JL, Nadig SN, Dubay DA, : A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant 20: 1969–1983, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Schinstock CA, Dadhania DM, Everly MJ, Smith B, Gandhi M, Farkash E, et al.: Factors at de novo donor-specific antibody initial detection associated with allograft loss: A multicenter study. Transpl Int 32: 502–515, 2019 PubMed

Schinstock CA, Dadhania DM, Everly MJ, Smith B, Gandhi M, Farkash E, : Factors at de novo donor-specific antibody initial detection associated with allograft loss: A multicenter study. Transpl Int 32: 502–515, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Schinstock CA, Cosio F, Cheungpasitporn W, Dadhania DM, Everly MJ, Samaniego-Picota MD, et al.: The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss. Am J Transplant 17: 1574–1584, 2017 PubMed

Schinstock CA, Cosio F, Cheungpasitporn W, Dadhania DM, Everly MJ, Samaniego-Picota MD, : The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss. Am J Transplant 17: 1574–1584, 2017PubMed)| false
• Search Google Scholar
• Export Citation

Nevins TE, Nickerson PW, Dew MA: Understanding medication nonadherence after kidney transplant. J Am Soc Nephrol 28: 2290–2301, 2017 PubMed

Nevins TE, Nickerson PW, Dew MA: Understanding medication nonadherence after kidney transplant. J Am Soc Nephrol 28: 2290–2301, 2017PubMed)| false
• Search Google Scholar
• Export Citation

Lim WH, Chapman JR, Coates PT, Lewis JR, Russ GR, Watson N, et al.: HLA-DQ mismatches and rejection in kidney transplant recipients. Clin J Am Soc Nephrol 11: 875–883, 2016 PubMed

Lim WH, Chapman JR, Coates PT, Lewis JR, Russ GR, Watson N, : HLA-DQ mismatches and rejection in kidney transplant recipients. Clin J Am Soc Nephrol 11: 875–883, 2016PubMed)| false
• Search Google Scholar
• Export Citation

DeVos JM, Gaber AO, Knight RJ, Land GA, Suki WN, Gaber LW, et al.: Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 82: 598–604, 2012 PubMed

DeVos JM, Gaber AO, Knight RJ, Land GA, Suki WN, Gaber LW, : Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 82: 598–604, 2012PubMed)| false
• Search Google Scholar
• Export Citation

Duquesnoy RJ, Askar M: HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 68: 12–25, 2007 PubMed

Duquesnoy RJ, Askar M: HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 68: 12–25, 2007PubMed)| false
• Search Google Scholar
• Export Citation

Wiebe C, Kosmoliaptsis V, Pochinco D, Gibson IW, Ho J, Birk PE, et al.: HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. Am J Transplant 19: 1708–1719, 2019 PubMed

Wiebe C, Kosmoliaptsis V, Pochinco D, Gibson IW, Ho J, Birk PE, : HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. Am J Transplant 19: 1708–1719, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Senev A, Coemans M, Lerut E, Van Sandt V, Kerkhofs J, Daniëls L, et al.: Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: An observational cohort study. J Am Soc Nephrol 31: 2193–2204, 2020 PubMed

Senev A, Coemans M, Lerut E, Van Sandt V, Kerkhofs J, Daniëls L, : Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: An observational cohort study. J Am Soc Nephrol 31: 2193–2204, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Kramer C, Heidt S, Claas FHJ: Towards the identification of the relative immunogenicity of individual HLA antibody epitopes. Hum Immunol 80: 218–220, 2019 PubMed

Kramer C, Heidt S, Claas FHJ: Towards the identification of the relative immunogenicity of individual HLA antibody epitopes. Hum Immunol 80: 218–220, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Tambur AR, Kosmoliaptsis V, Claas FHJ, Mannon RB, Nickerson P, Naesens M: Significance of HLA-DQ in kidney transplantation: Time to reevaluate human leukocyte antigen-matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney Int 100: 1012–1022, 2021 PubMed

Tambur AR, Kosmoliaptsis V, Claas FHJ, Mannon RB, Nickerson P, Naesens M: Significance of HLA-DQ in kidney transplantation: Time to reevaluate human leukocyte antigen-matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney Int 100: 1012–1022, 2021PubMed)| false
• Search Google Scholar
• Export Citation

Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al.: Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 Expert Consensus from the Transplantation Society Working Group. Transplantation 104: 911–922, 2020 PubMed

Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, : Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 Expert Consensus from the Transplantation Society Working Group. Transplantation 104: 911–922, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Bailly E, Ville S, Blancho G, Morelon E, Bamoulid J, Caillard S, et al.: An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. Transpl Int 33: 786–795, 2020 PubMed

Bailly E, Ville S, Blancho G, Morelon E, Bamoulid J, Caillard S, : An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. Transpl Int 33: 786–795, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, et al.: One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation 100: 391–399, 2016 PubMed

Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, : One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation 100: 391–399, 2016PubMed)| false
• Search Google Scholar
• Export Citation

Marks WH, Mamode N, Montgomery RA, Stegall MD, Ratner LE, Cornell LD, et al.; C10-001 Study Group: Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. Am J Transplant 19: 2876–2888, 2019 PubMed

Marks WH, Mamode N, Montgomery RA, Stegall MD, Ratner LE, Cornell LD, ; C10-001 Study Group: Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. Am J Transplant 19: 2876–2888, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, Chadban S, et al.; C10-002 Study Group: Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. Am J Transplant 19: 2865–2875, 2019 PubMed

Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, Chadban S, ; C10-002 Study Group: Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. Am J Transplant 19: 2865–2875, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Schinstock CA, Bentall AJ, Smith BH, Cornell LD, Everly M, Gandhi MJ, et al.: Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. Am J Transplant 19: 1671–1683, 2019 PubMed

Schinstock CA, Bentall AJ, Smith BH, Cornell LD, Everly M, Gandhi MJ, : Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. Am J Transplant 19: 1671–1683, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Tan EK, Bentall A, Dean PG, Shaheen MF, Stegall MD, Schinstock CA: Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: A consecutive series of 15 cases. Transplantation 103: 2397–2404, 2019 PubMed

Tan EK, Bentall A, Dean PG, Shaheen MF, Stegall MD, Schinstock CA: Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: A consecutive series of 15 cases. Transplantation 103: 2397–2404, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Montgomery RA, Orandi BJ, Racusen L, Jackson AM, Garonzik-Wang JM, Shah T, et al.: Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: Results of a randomized double-blind placebo-controlled pilot study. Am J Transplant 16: 3468–3478, 2016 PubMed

Montgomery RA, Orandi BJ, Racusen L, Jackson AM, Garonzik-Wang JM, Shah T, : Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: Results of a randomized double-blind placebo-controlled pilot study. Am J Transplant 16: 3468–3478, 2016PubMed)| false
• Search Google Scholar
• Export Citation

Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A, et al.: C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: A pilot study. Am J Transplant 16: 1596–1603, 2016 PubMed

Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A, : C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: A pilot study. Am J Transplant 16: 1596–1603, 2016PubMed)| false
• Search Google Scholar
• Export Citation

Doberer K, Kläger J, Gualdoni GA, Mayer KA, Eskandary F, Farkash EA, et al.: CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation 105: 451–457, 2021 PubMed

Doberer K, Kläger J, Gualdoni GA, Mayer KA, Eskandary F, Farkash EA, : CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation 105: 451–457, 2021PubMed)| false
• Search Google Scholar
• Export Citation

Jain D, Rajab A, Young JS, Yin D, Nadasdy T, Chong AS, et al.: Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. Am J Transplant 20: 2675–2685, 2020 PubMed

Jain D, Rajab A, Young JS, Yin D, Nadasdy T, Chong AS, : Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. Am J Transplant 20: 2675–2685, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Jordan SC, Legendre C, Desai NM, Lorant T, Bengtsson M, Lonze BE, et al.: Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: Results of an international phase 2 trial (Highdes). Transplantation 105: 1808–1817, 2021 PubMed

Jordan SC, Legendre C, Desai NM, Lorant T, Bengtsson M, Lonze BE, : Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: Results of an international phase 2 trial (Highdes). Transplantation 105: 1808–1817, 2021PubMed)| false
• Search Google Scholar
• Export Citation

Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B, et al.: Interleukin-6, A cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: Therapeutic implications of IL-6 receptor blockade. Transplantation 101: 32–44, 2017 PubMed

Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B, : Interleukin-6, A cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: Therapeutic implications of IL-6 receptor blockade. Transplantation 101: 32–44, 2017PubMed)| false
• Search Google Scholar
• Export Citation

Shin BH, Everly MJ, Zhang H, Choi J, Vo A, Zhang X, et al.: Impact of tocilizumab (anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation 104: 856–863, 2020 PubMed

Shin BH, Everly MJ, Zhang H, Choi J, Vo A, Zhang X, : Impact of tocilizumab (anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation 104: 856–863, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Pottebaum AA, Venkatachalam K, Liu C, Brennan DC, Murad H, Malone AF, et al.: Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct 6: e543, 2020 PubMed

Pottebaum AA, Venkatachalam K, Liu C, Brennan DC, Murad H, Malone AF, : Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct 6: e543, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, et al.: Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 17: 2381–2389, 2017 PubMed

Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, : Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 17: 2381–2389, 2017PubMed)| false
• Search Google Scholar
• Export Citation

Massat M, Congy-Jolivet N, Hebral AL, Esposito L, Marion O, Delas A, et al.; Toulouse Acquired Immune Deficiency, Infection (TAIDI) Study Group: Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant 21: 1641–1649, 2021 PubMed

Massat M, Congy-Jolivet N, Hebral AL, Esposito L, Marion O, Delas A, ; Toulouse Acquired Immune Deficiency, Infection (TAIDI) Study Group: Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant 21: 1641–1649, 2021PubMed)| false
• Search Google Scholar
• Export Citation

Eskandary F, Dürr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, et al.: Clazakizumab in late antibody-mediated rejection: Study protocol of a randomized controlled pilot trial. Trials 20: 37, 2019 PubMed

Eskandary F, Dürr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, : Clazakizumab in late antibody-mediated rejection: Study protocol of a randomized controlled pilot trial. Trials 20: 37, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, et al.: A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 32: 708–722, 2021 PubMed

Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, : A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 32: 708–722, 2021PubMed)| false
• Search Google Scholar
• Export Citation

CSL Behring: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (IMAGINE), 2021. Available at: https://clinicaltrials.gov/ct2/show/NCT03744910. Accessed August 15, 2021

Billingham RE, Brent L, Medawar PB: Actively acquired tolerance of foreign cells. Nature 172: 603–606, 1953 PubMed

Billingham RE, Brent L, Medawar PB: Actively acquired tolerance of foreign cells. Nature 172: 603–606, 1953PubMed)| false
• Search Google Scholar
• Export Citation

Rickert CG, Markmann JF: Current state of organ transplant tolerance. Curr Opin Organ Transplant 24: 441–450, 2019 PubMed

Rickert CG, Markmann JF: Current state of organ transplant tolerance. Curr Opin Organ Transplant 24: 441–450, 2019PubMed)| false
• Search Google Scholar
• Export Citation

Newell KA, Adams AB, Turka LA: Biomarkers of operational tolerance following kidney transplantation: The immune tolerance network studies of spontaneously tolerant kidney transplant recipients. Hum Immunol 79: 380–387, 2018 PubMed

Newell KA, Adams AB, Turka LA: Biomarkers of operational tolerance following kidney transplantation: The immune tolerance network studies of spontaneously tolerant kidney transplant recipients. Hum Immunol 79: 380–387, 2018PubMed)| false
• Search Google Scholar
• Export Citation

Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, et al.: Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120: 1848–1861, 2010 PubMed

Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, : Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120: 1848–1861, 2010PubMed)| false
• Search Google Scholar
• Export Citation

Busque S, Scandling JD, Lowsky R, Shizuru J, Jensen K, Waters J, et al.: Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Sci Transl Med 12: eaax8863, 2020 PubMed

Busque S, Scandling JD, Lowsky R, Shizuru J, Jensen K, Waters J, : Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Sci Transl Med 12: eaax8863, 2020PubMed)| false
• Search Google Scholar
• Export Citation

Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, et al.: Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. Am J Transplant 15: 695–704, 2015 PubMed

Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, : Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. Am J Transplant 15: 695–704, 2015PubMed)| false
• Search Google Scholar
• Export Citation

Leventhal J, Galvin J, Mathew J, Gallon L, Stare D, Sweeney A, Miller J, Abecassis M, Ildstad S. Eight year follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients. Am J Transplant 17(Suppl 3): 276, 2017

Leventhal J, Galvin J, Mathew J, Gallon L, Stare D, Sweeney A, Miller J, Abecassis M, Ildstad S. Eight year follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients. Am J Transplant 17(Suppl 3): 276, 2017)| false
• Search Google Scholar
• Export Citation

Issa F, Strober S, Leventhal JR, Kawai T, Kaufman DB, Levitsky J, et al.: The Fourth International Workshop on Clinical Transplant Tolerance. Am J Transplant 21: 21–31, 2021 PubMed

Issa F, Strober S, Leventhal JR, Kawai T, Kaufman DB, Levitsky J, : The Fourth International Workshop on Clinical Transplant Tolerance. Am J Transplant 21: 21–31, 2021PubMed)| false
• Search Google Scholar
• Export Citation

Sellberg F, Berglund D, Binder C, Hope J, Fontenot J, Griesemer A, et al.: Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody. Scand J Immunol 91: e12839, 2020 PubMed

Sellberg F, Berglund D, Binder C, Hope J, Fontenot J, Griesemer A, : Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody. Scand J Immunol 91: e12839, 2020PubMed)| false
• Search Google Scholar
• Export Citation